Recursion Pharmaceuticals (NASDAQ: RXRX) announced that co-founder and board chair Chris Gibson will not stand for reelection at the company's upcoming annual meeting on June 17. The move comes just months after he stepped down as chief executive officer in a leadership transition that began last November.
Gibson, who founded the Salt Lake City-based biotech firm, informed the board on April 28 of his decision not to seek another term as a Class II director. According to a regulatory filing, his departure is not related to any disagreement with company policies or operations. He will remain chairman until his current term concludes.
The timing of this board change is significant as Recursion prepares to release its first-quarter financial results on May 6 before the market opens. Investors will be scrutinizing the earnings call for updates on the company's cash position, clinical trial timelines, and progress with its artificial intelligence-driven drug discovery platform.
At the end of 2025, Recursion reported $753.9 million in cash, cash equivalents, and restricted cash, which management says should fund operations into early 2028 without requiring additional financing. The company also narrowed its net loss to $108.1 million in the fourth quarter, compared to $178.9 million in the same period a year earlier, while fourth-quarter revenue surged to $35.5 million from $4.5 million. CEO Najat Khan described the quarter as an inflection point.
Gibson's departure marks the latest change in Recursion's leadership structure. In November, the company announced that Khan would become CEO and president effective January 1, while Gibson transitioned to chairman and interim executive adviser. Rob Hershberg was appointed vice-chairman and lead independent director at that time.
The company's lead pipeline candidate, REC-4881, targets familial adenomatous polyposis (FAP), a genetic disorder that causes hundreds to thousands of polyps in the colon and rectum, significantly increasing colorectal cancer risk if untreated. Progress on this drug remains a key focus for analysts and shareholders.
Wall Street sentiment toward Recursion is cautiously optimistic but lacks consensus. According to StockAnalysis, JPMorgan analyst Priyanka Grover reiterated a Buy rating on April 30, though she lowered her price target to $10 from $11. The stock is covered by five analysts with an average price target of $8.00.
Recursion shares traded at $3.44 on Friday afternoon, giving the company a market capitalization of approximately $1.54 billion. The stock remains in high-risk biotech territory, as the company has yet to bring any commercial medicines to market. In its annual report, Recursion acknowledged it has no approved products, zero product revenue, and expects continued losses, potentially requiring a significant capital raise that could dilute existing shareholders.
The company competes with other AI-driven drug discovery firms such as Certara and Schrödinger. Recursion made headlines last year by acquiring smaller rival Exscientia in an all-stock deal valued at $688 million, aiming to strengthen its AI-powered drug development toolkit.
Shareholders are expected to participate in the virtual annual meeting on June 17 at noon Mountain Time. The agenda includes election of two Class II directors, an advisory vote on executive compensation, and ratification of PricewaterhouseCoopers as the company's independent auditor. As of the April 21 record date, there were approximately 524.6 million Class A shares and 5.3 million Class B shares outstanding.